Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, GLP-1RA + Basal, Other Dec 22 | 2022Lilly Initiates Final Ph3 QWINT Trial; Madrigal Announces $300M+ in Financing Events to Advance Resmetirom; Akebia Receives Interim Response to Appeal for Vadadustat CRLPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Dec 21 | 2022Medtronic InPen App Recall; Libre 3 + Ypsomed AID Available in Germany; Altimmune Positive Pemvidutide NAFLD Data; Embecta CY Q3 ’22 Earnings Update; Alnylam Submits ALN-KHK CTA for T2DM; Biocorp Receives EU Medical Device CertificationPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Dec 19 | 2022Madrigal Wins Big with Ph3 NASH Data; Novo Expands Partnership for Dose Check; AZ Announces DELIVER Positive CHMP OpinionPurchase Blast
$599
Posted in: Other, SGLT2i Dec 16 | 2022Lilly Partners with Sosei Heptares for Metabolic Drug Discovery; FIGARO-DKD and DELIVER Positive CHMP OpinionsPurchase Blast
$599
Posted in: Other Dec 15 | 2022Alnylam Hosts 2022 R&D Day; Movano Health Initiates First Beta Program for Smart RingPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other Dec 14 | 2022Tandem Acquires Sigi Patch Pump; Novo Reports Ozempic Supply Shortages; Novo Initiates Second 7.2mg Sema Ph3 Trial in T2DM; Cytokinetics Host Post-adcom Investor CallPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other Dec 13 | 2022Lilly Green Lights Two Next-Gen Incretin Ph3 Programs; Lilly 2023 Guidance CallPurchase Blast
$599
Posted in: GLP-1RA, Other Dec 12 | 2022Pfizer Hosts 2022 R&D Day; Novo Initiates 7.2mg Sema Ph3 Obesity Trial; ADA 2023 Diabetes SoC Guidelines; December CHMP AgendaPurchase Blast
$599
Posted in: Insulin Delivery, Other Dec 09 | 2022Lilly Ends Ypsomed Partnership; Cytokinetics Adcom Documents AvailablePurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery Dec 07 | 2022Esperion’s CLEAR Outcomes CVOT Meets Primary Endpoint; Biocorp’s Mallya Receives FDA 510(k) Clearance; Jardiance Meets Primary Endpoint in Pediatric Trial; MediciNova MN-001 (tipelukast) T2DM and NAFLD Ph2 Data; Daewoong Looks to Commercialize Enavogliflozin GloballyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Dec 05 | 2022Amgen AMG 133 Updates @ WCIRDC 2022; Novo Initiates Ph3 Ziltivekimab Trial in HFPurchase Blast
$599
Posted in: Other Dec 02 | 2022Could Evkeeza’s New Peds Approval Result in a PRV for REGN?Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Nov 29 | 2022Biocon Completes Viatris Biosimilars Business Acquisition; Nemaura Launches Miboko Pilot Program in UK; BMS Terminates CV Partnership with uniQurePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Nov 28 | 2022Libre 3 + Ypsomed AID Authorized in Germany; Diamyd Ph3 T1DM Clinical Hold LiftedPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, SGLT2i Nov 23 | 2022Medtronic CY Q3 ’22 Earnings Update; Novo Expands Manufacturing Facilities; FDA Approves Lilly’s Rezvoglar as an Interchangeable Biosimilar; Oramed Presents Additional Ph2 PRMD-0801 NASH DataPurchase Blast
$599
Posted in: Other Nov 17 | 2022Teplizumab Approved as Tzield; Sernova Implants First Two Patients in Second Cohort of Ph1/2 T1DM TrialPurchase Blast
$599
Posted in: Insulin Delivery, Other Nov 16 | 2022Medtronic Launches Extended Wear Infusion Set; Dario Q3 ’22 Earnings Update; Versanis Bio Initiates Ph2 Bimagrumab Study in ObesityPurchase Blast